Ultragenyx Pharmaceutical Inc.
NEWS
Under the terms of the deal, Utragenyx will pay GeneTx $20 million for an exclusive option to acquire GeneTx.
Ultragenyx Pharmaceutical Inc. and GeneTx Biotherapeutics LLC announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, a serious, debilitating, rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide.
Ultragenyx Pharmaceutical Inc. announced that Tom Kassberg, the company’s Chief Business Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 1:20 PM ET in New York, NY.
Ultragenyx Pharmaceutical Inc. reported its financial results and corporate update for the quarter ended June 30, 2019.
Ultragenyx Pharmaceutical Inc. announced that it has submitted to the U.S. Food and Drug Administration a New Drug Application for UX007 for the treatment of long-chain fatty acid oxidation disorders, a group of genetic disorders in which the body is unable to convert long-chain fatty acids into energy.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update.
Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics
Ultragenyx Pharmaceutical Inc. announced it has promoted Erik Harris to Executive Vice President and Chief Commercial Officer, effective June 11, 2019.
Ultragenyx Pharmaceutical Inc. announced that it will present at the following upcoming investor conferences
JOBS
IN THE PRESS